Selected article for: "host immune response avoid and immune response"

Author: Nypaver, Cynthia; Dehlinger, Cynthia; Carter, Chelsea
Title: Influenza and Influenza Vaccine: A Review [Image: see text]
  • Cord-id: qnefrdjy
  • Document date: 2021_2_1
  • ID: qnefrdjy
    Snippet: Influenza is a highly contagious, deadly virus, killing nearly half a million people yearly worldwide. The classic symptoms of influenza are fever, fatigue, cough, and body aches. In the outpatient setting, diagnosis can be made by clinical presentation with optional confirmatory diagnostic testing. Antiviral medications should be initiated as soon as possible, preferably within 24 hours of initiation of symptoms. The primary preventive measure against influenza is vaccination, which is recommen
    Document: Influenza is a highly contagious, deadly virus, killing nearly half a million people yearly worldwide. The classic symptoms of influenza are fever, fatigue, cough, and body aches. In the outpatient setting, diagnosis can be made by clinical presentation with optional confirmatory diagnostic testing. Antiviral medications should be initiated as soon as possible, preferably within 24 hours of initiation of symptoms. The primary preventive measure against influenza is vaccination, which is recommended for all people 6 months of age or older, including pregnant and postpartum women, unless the individual has a contraindication. Vaccination should occur at the beginning of flu season, which typically begins in October. It takes approximately 14 days after vaccination for a healthy adult to reach peak antibody protection. There are challenges associated with vaccine composition and vaccine uptake. It takes approximately 6 to 8 months to identify and predict which influenza strains to include in the upcoming season's vaccine. During this time, the influenza virus may undergo antigenic drift, that is, mutating to avoid a host immune response. Antigenic drift makes the vaccine less effective in some seasons. The influenza virus occasionally undergoes antigenic shift, in which it changes to a novel virus, creating potential for a pandemic. There are also barriers to vaccine uptake, including lack of or limited access to care and misconceptions about receiving the vaccine. Interventions that improve access to and uptake of the influenza vaccine must be initiated, targeting multiple levels, including health care policy, patients, health care systems, and the health care team. This article reviews information about influenza identification, management, and prevention.

    Search related documents:
    Co phrase search for related documents
    • access increase and action mechanism: 1
    • access increase and acute respiratory illness: 1
    • acellular tdap pertussis and acip immunization practices: 1, 2, 3
    • acellular tdap pertussis and acip immunization practices advisory committee: 1, 2, 3
    • acellular tdap pertussis vaccine and acip immunization practices: 1, 2
    • acellular tdap pertussis vaccine and acip immunization practices advisory committee: 1, 2
    • acellular tdap pertussis vaccine diphtheria toxoid and acip immunization practices: 1
    • acellular tdap pertussis vaccine diphtheria toxoid and acip immunization practices advisory committee: 1
    • acid amplification test and acute respiratory illness: 1
    • acip immunization practices advisory committee and additional guidance: 1
    • acip immunization practices and additional guidance: 1
    • action mechanism and acute respiratory illness: 1, 2, 3, 4